-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There is a lack of evidence
on the effectiveness of prophylactic tranexamic acid (TXA) in the treatment of thrombocytopenia.
To determine whether TXA can safely reduce bleeding rates in patients with treated hematologic malignancies, the researchers conducted a randomized, double-blind clinical trial (June 2016-June 2020
).
A total of 3120 patients were screened, of which 356 were eligible to be included in the trial, and finally 337 patients (mean 53.
9 years, 141 [41.
8%] women) were randomized to receive 1300 mg of TXA orally or 1000 mg of TXA intravenous drip (n=168) or placebo (n=169) 3 times/day for a maximum of 30 days
of continued treatment.
Proportion of patients without WHO ≥ grade 2 bleeding or death
When the platelet count is below 30000/μL, 333 patients are activated; 279-bit (83%) have a complete prognostic assessment
.
Security endpoint
The most common adverse events were diarrhea (TXA vs placebo: 70.
In short, in patients with hematologic malignancies who received chemotherapy or hematopoietic stem cell transplantation, prophylactic treatment of TXA did not significantly reduce the risk of
bleeding grade 2 in WHO ≥ compared with placebo.
Original Source:
Terry B.
